Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Imclone systems (IMCL) -- Ignore unavailable to you. Want to Upgrade?

To: JEB who wrote (1110)	12/15/1999 7:46:00 AM
From: Paul A	Read Replies (1) \| Respond to of 2515

here ya go: biz.yahoo.com

To: JEB who wrote (1110)	12/27/1999 9:56:00 AM
From: Eric Savage	Respond to of 2515

Related QuotesIMCL 39 5/8 +5/8 delayed 20 mins - disclaimer Thursday December 23, 9:40 am Eastern Time RESEARCH ALERT-ImClone earnings estimates revised NEW YORK, Dec 23 (Reuters) - Warburg Dillon Read said Thursday it is raising its 1999 loss estimate for ImClone Systems Inc. (NasdaqNM:IMCL - news) to $1.52 from $0.50 but trimming its 2000 loss estimate to $0.74 from $1.16. -- report said revising its estimates based on a delay in recognizing a milestone payment from its partner Merck KGaA related to its lead cancer product C225. ``While ImClone has actually received $20 million of this payment thus far, recognition of the milestone as revenue will not occur until 1Q00.'